<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177576</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/50</org_study_id>
    <nct_id>NCT04177576</nct_id>
  </id_info>
  <brief_title>Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms</brief_title>
  <acronym>MPN-BIOCLOT</acronym>
  <official_title>Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative
      neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive.
      Neutrophils can release their decondensed chromatin as a network of extracellular fibers
      named NET for &quot;neutrophils extracellular trap&quot;. NETs are known to be procoagulant. Our main
      objective is to quantify NETs biomarkers expression in MPN patients and define if they could
      be used as prognostic factors in the outcome of thrombosis in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myeloproliferative neoplasms (MPN) are acquired clonal hematopoietic stem cell disorders,
      characterized by an increase in one or more myeloid lineages. The Philadelphia chromosome
      negative (Ph-) MPN include polycythemia vera (PV) with an excess of red blood cells,
      essential thrombocythemia (ET) with an increase in platelets and primary myelofibrosis (PMF).
      Arterial and venous thromboses are the main causes of morbidity and mortality in MPN with
      reported incidences ranging from 12-39% in PV and 11-25% in ET. The pathogenesis of
      thrombosis in MPN patients is complex and still largely elusive. The overproduction of
      neutrophils could be an important risk factor in the thrombus formation. Indeed neutrophils
      are known to promote thrombosis when they release their decondensed chromatin as a network of
      extracellular fibers named NET for &quot;neutrophils extracellular trap&quot;. Increased NETosis has
      been reported in a mouse model of MPN. The main objective of this study is to investigate
      whether NET biomarkers are associated with increased thrombotic risk in patients with ET.
      Indeed, an international thrombotic prognostic score has been published in ET, ie the IPSET
      Thrombosis score (history of thrombosis, age, presence of JAK2V617F, cardiovascular risk
      factors).

      Plasma from MPN patients will be collected, at the time of diagnosis, and measure markers of
      neutrophil activation, including NET biomarkers. The IPSET Thrombosis score will be evaluated
      in patients with ET and the correlation between the IPSET Thrombosis score and these
      biomarkers will be measured.

      No follow-up is required for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between NET biomarkers and the risk of thrombosis</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between NET biomarkers measurated in plasma samples and the risk of thrombosis evaluated by the prognostic score IPSET thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between MPO-DNA levels (measured by absorbance at 405 nm) and a history of thrombosis</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between MPO-DNA levels (measured by absorbance at 405 nm) and the subtype of MPN disease (ET or PV)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between MPO-DNA levels (measured by absorbance at 405 nm) and the presence of JAK2V617F mutation</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Patients with myeloproliferative neoplasms (MPN)</arm_group_label>
    <description>Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 additional tubes of blood</intervention_name>
    <description>2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation</description>
    <arm_group_label>Patients with myeloproliferative neoplasms (MPN)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma aliquots
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with myeloproliferative neoplasms (MPN), diagnosed with Polycythemia vera (PV) or
        essential thrombocythemia (ET)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age ≥18 years),

          -  Patients diagnosed with Polycythemia vera (PV) or essential thrombocythemia (ET)
             according to WHO 2008 criteria,

          -  Affiliated to the national social security system,

          -  Signed informed consent form will be required for each included subject after having
             read the information note,

          -  Patient agreeing to be included in the FIMBANK register and having signed the
             corresponding consent

        Exclusion Criteria:

          -  Adults (age &gt;18 years), male or female,

          -  Patients treated with heparin or undergoing cytoreductive treatment,

          -  Pregnant or lactating woman,

          -  Person under guardianship, tutorship or other legal protection scheme or incapable of
             giving consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chloé JAMES</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloé JAMES</last_name>
    <phone>+33 (0)5 57 65 64 78</phone>
    <email>chloe.james@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre GUY</last_name>
    <email>alexandre.guy@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise BOYER</last_name>
      <email>Frboyer-perrard@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale CONY-MAKHOUL</last_name>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Borhane SLAMA</last_name>
      <email>bslama@ch-avignon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux, Hématologie Biologique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cholé JAMES</last_name>
      <email>chloe.james@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux, Hématologie Clinique et Thérapie Cellulaire</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axelle LASCAUX</last_name>
      <email>axelle.lascaux@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux, Médecine Interne</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François VIALLARD</last_name>
      <email>jean-francois.viallard@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel ETIENNE</last_name>
      <email>G.Etienne@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe IANOTTO</last_name>
      <email>jean-christophe.ianotto@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - APHP</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lydia ROY</last_name>
      <email>lydia.roy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure STALNIKIEWICZ</last_name>
      <email>lstalnikiewicz@ch-lens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane GIRAULT</last_name>
      <email>stephane.girault@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck-Emmanuel NICOLINI</last_name>
      <email>franck-emmanuel.nicolini@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud SAINT LEZER</last_name>
      <email>arnaud.saint-lezer@ch-mdm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc DARNIGE</last_name>
      <email>luc.darnige@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Jacques KILADJIAN</last_name>
      <email>jean-jacques.kiladjian@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loula PAPAGEORGIOU</last_name>
      <email>loula.papageorgiou@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabienne VACHERET</last_name>
      <email>fabienne.vacheret@ch-perpignan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie CAYSSIALS</last_name>
      <email>Emilie.CAYSSIALS@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Rochefort</name>
      <address>
        <city>Rochefort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume DENIS</last_name>
      <email>guillaume.denis@ch-rochefort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu WEMEAU</last_name>
      <email>mathieu.wemeau@ch-roubaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopôle</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne TAVITIAN</last_name>
      <email>tavitian.suzanne@iuctoncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie CAMBIER</last_name>
      <email>cambier-n@ch-valenciennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence GROS</last_name>
      <email>Laurence.legros@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia Vera (PV)</keyword>
  <keyword>Essential Thrombocythemia (ET)</keyword>
  <keyword>Neutrophil Extracellular Trap (NET)</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

